IHC analysis of tumors resected at the end of treatment (Figure 6, B and C) mirrored the survival benefit, with optimized paxalisib and enzastaurin decreasing tumor burden (H3K27M and Ki67), potentiated by the combination. This evidence concerns the gene MKI67 and neoplasm.